Key result
In patients at medium Framingham cardiovascular risk, the presence of chronic kidney disease was associated with a significantly higher 10-year cardiovascular event rate (26.7%) compared to those without chronic kidney disease (6.6%).
Why the study?
Does the presence of chronic kidney disease (CKD) improve cardiovascular risk prediction in patients at medium Framingham risk?
Cohort (n=905)
No
Does the presence of chronic kidney disease (CKD) improve cardiovascular risk prediction in patients at medium Framingham risk?
Absolute Event Rate: 26.7% vs 6.6%
p-value: p=0.005
Factoring in chronic kidney disease enhances cardiovascular risk stratification in patients at medium Framingham risk, identifying a subgroup at significantly higher risk of events.
Based on global cardiovascular (CV) risk assessment for example using the Framingham risk score, it is recommended that those with high risk should be treated and those with low risk should not be treated. The recommendation for those of medium risk is less clear and uncertain. We aimed to determine whether factoring in chronic kidney disease (CKD) will improve CV risk prediction in those with medium risk. This is a 10-year retrospective cohort study of 905 subjects in a primary care clinic setting. Baseline CV risk profile and serum creatinine in 1998 were captured from patients record. Framingham general cardiovascular disease risk score (FRS) for each patient was computed. All cardiovascular disease (CVD) events from 1998-2007 were captured. Overall, patients with CKD had higher FRS risk score (25.9% vs 20%, p = 0.001) and more CVD events (22.3% vs 11.9%, p = 0.002) over a 10-year period compared to patients without CKD. In patients with medium CV risk, there was no significant difference in the FRS score among those with and without CKD (14.4% vs 14.6%, p = 0.84) However, in this same medium risk group, patients with CKD had more CV events compared to those without CKD (26.7% vs 6.6%, p = 0.005). This is in contrast to patients in the low and high risk group where there was no difference in CVD events whether these patients had or did not have CKD. There were more CV events in the Framingham medium risk group when they also had CKD compared those in the same risk group without CKD. Hence factoring in CKD for those with medium risk helps to further stratify and identify those who are actually at greater risk, when treatment may be more likely to be indicated.
No takes yet. Share an insight, caveat, or question.
Chia et al. (2015) conducted a cohort in Medium cardiovascular risk (n=905). Chronic kidney disease vs. No chronic kidney disease was evaluated on 10-year cardiovascular disease events in the medium risk group (p=0.005). In patients at medium Framingham cardiovascular risk, the presence of chronic kidney disease was associated with a significantly higher 10-year cardiovascular event rate (26.7%) compared to those without chronic kidney disease (6.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: